Behavioral Health Integration (BHI) and Secondary Hyperparathyroidism (SHPT) are two opportunities for patient improvement and additional revenue for CeutiCare customers.
2017 CMS CCM rules include billing codes for BHI services.
Depending on the patient population, between 25% and 90% of those patients that qualify for CCM benefits are also being treated for depression with psychotropic drugs. CeutiCare's medication review services qualify for BHI reimbusement under the CCM program. CeutiCare also checks for Beer's list drugs should not be prescribed to elderly patients. BHI and CCM services can both be provided to the same patient in the same month.
Secondary Hyperparathyroidism is a condition that 35% - 50% of Chronic Kidney Disease patients suffer from. Is in under diagnosed. It weakens the bones so falls become breaks. It calcifies the software tissue accelerating kidney failure and increasing the risk of heart attacks and strokes. Screening and treatment preserves kidney function and delays the need for dialysis. It generates significant additional revenue for the practice and the lab. CeutiCare has been able to return the PTH of 99% of SHPT patients to manageable levels in 60 days.
BHI and SHPT are two additional revenue opportunities available to CeutiCare customers.
These services are not available from CCM vendors offering case management solutions.
Contact CeutiCare for more information on how you can take advantage of these opportunities.